Patients with PEL are conventionally treated with anthracycline-containing chemotherapy regimens, however further targeted therapies [e.g. lena/pomalidomide, PDl-1 inhibition] are also being studied, and survival expectations have continued to improve [10], [11]. The gene discussed is CD274; the disease is primary effusion lymphoma.